TY - JOUR
T1 - Expert consensus from the Arabian Gulf on selecting disease-modifying treatment for people with multiple sclerosis according to disease activity
AU - Alroughani, Raed
AU - Inshasi, Jihad
AU - Al-Asmi, Abdullah
AU - Alqallaf, Abdulradha
AU - Al Salti, Abdulla
AU - Shatila, Ahmed
AU - Boshra, Amir
AU - Canibano, Beatriz
AU - Deleu, Dirk
AU - Al Sharoqi, Isa
AU - Al Khabouri, Jaber
N1 - Funding Information:
All authors participated in the closed meeting that gave rise to this article, which was organized by Merck Serono Middle East FZ-Ltd, United Arab Emirates, an affiliate of Merck KGaA, Darmstadt, Germany. JI, AA, AAS, IA, and JAK declared no additional duality of interest. Additional duality of interest declarations are as follows. RA received honoraria as a speaker and for serving in scientific advisory boards from Bayer, Biogen, Merck, Novartis, Roche, and Sanofi. AA-A received honoraria for serving on scientific advisory boards from Merck, Novartis, Roche, and Sanofi, and also received travel reimbursement from Biologix, Sanofi, Merck, Roche, Bayer, and Novartis. AS received honoraria for lectures from Sanofi-Genzyme, Merck, Genpharm, Roche, Novartis, Boehringeringer Ingelheim, and Biologix, and for advisory boards from Sanofi-Genzyme, Roche, Novartis, Pfizer, and Biologix, and received financial support for registration, accommodation, and travel for conferences provided by Sanofi-Genzyme, Merck, Genpharm, Roche, Novartis, and Biologix. BC has received travel, speaker, and consultant honoraria from Merck, Novartis, Biologix, Roche, and Sanofi. DD has presented at meetings and served in scientific advisory boards from Biogen, Merck, Novartis, Roche, and Sanofi. AB is an employee of Merck Serono Middle East FZ-Ltd, United Arab Emirates, an affiliate of Merck KGaA, Darmstadt, Germany.
Funding Information:
Medical writing support was provided by Dr Mike Gwilt of GT Communications, funded by Merck Serono Middle East FZ-ltd, United Arab Emirates, an affiliate of Merck KGaA, Darmstadt, Germany.
Publisher Copyright:
© 2020, © 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2020/5/18
Y1 - 2020/5/18
N2 - Recent research has expanded our understanding of the natural history and clinical course of multiple sclerosis (MS) in the Arabian Gulf region. In addition, the number of available therapies for MS has increased greatly in recent years, which complicates considerably the design of therapeutic regimens. We, an expert group of physicians practising in Arabian Gulf countries, present pragmatic consensus recommendations for the use of disease-modifying therapy, according to the level of MS disease activity, according to objective criteria, and prior treatment (if any) received by a given patient.
AB - Recent research has expanded our understanding of the natural history and clinical course of multiple sclerosis (MS) in the Arabian Gulf region. In addition, the number of available therapies for MS has increased greatly in recent years, which complicates considerably the design of therapeutic regimens. We, an expert group of physicians practising in Arabian Gulf countries, present pragmatic consensus recommendations for the use of disease-modifying therapy, according to the level of MS disease activity, according to objective criteria, and prior treatment (if any) received by a given patient.
KW - Multiple sclerosis
KW - consensus statement
KW - disease-modifying therapy
UR - http://www.scopus.com/inward/record.url?scp=85080133452&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85080133452&partnerID=8YFLogxK
U2 - 10.1080/00325481.2020.1734394
DO - 10.1080/00325481.2020.1734394
M3 - Review article
C2 - 32089038
AN - SCOPUS:85080133452
SN - 0032-5481
VL - 132
SP - 368
EP - 376
JO - Postgraduate Medicine
JF - Postgraduate Medicine
IS - 4
ER -